News & Events
Wednesday, February 17, 2010
Soligenix Announces Issuance of Hong Kong Patent for its LPM™ Oral Drug Delivery Technology
[read more]Wednesday, February 03, 2010
Soligenix to Present at 12th Annual BIO CEO & Investor Conference
[read more]Tuesday, February 02, 2010
Soligenix Announces Publication of Positive Stability Results with RiVax™, its Vaccine Against Ricin Toxin
Preclinical Data Demonstrate the Potential for Long-term Stability of RiVax™ [read more]Monday, December 28, 2009
Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax™, its Vaccine Against Ricin Toxin
Collaborative Effort Between Soligenix and Wadsworth Center Describes the Properties of Protective Antibodies to Ricin Toxin
[read more]Monday, December 21, 2009
Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201
for the Prevention of Acute Radiation Enteritis
[read more]Friday, November 20, 2009
Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax™ and Other Rapidly Acting Vaccines
[read more]Friday, November 13, 2009
Soligenix Reports Third Quarter 2009 Financial Results
[read more]Tuesday, October 27, 2009
Soligenix to Present at 8th Annual BIO Investor Forum
Presentation at 1PM PDT, Thursday, October 29, Available by Webcast
[read more]Wednesday, October 21, 2009
Soligenix to Provide Corporate Update
[read more]Thursday, October 15, 2009
Soligenix Announces Initiation of its Confirmatory Phase 3 Clinical Trial of orBec® in Acute GI GVHD
[read more]Friday, October 09, 2009
Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
[read more]Wednesday, September 30, 2009
DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol “SNGX”
[read more]Thursday, September 24, 2009
DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
[read more]Monday, September 21, 2009
DOR BioPharma Announces $9.4 Million NIH Grant Award to
Develop Thermostable and Rapidly Acting Vaccines
[read more]Tuesday, September 08, 2009
DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
[read more]Thursday, September 03, 2009
DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference,
Presentation to be Webcast Live
[read more]Friday, August 14, 2009
DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
[read more]Tuesday, August 04, 2009
DOR BioPharma Receives FDA Orphan Drug Designation for orBec® for the Treatment of Chronic Gastrointestinal GVHD
[read more]Wednesday, July 08, 2009
DOR BioPharma Announces Issuance of European Patent for its LPM™ Oral Drug Delivery Technology
[read more]Tuesday, July 07, 2009
DOR BioPharma Announces Christopher P. Schnittker, CPA, as Vice President of Administration and Controller
[read more]Monday, June 29, 2009
DOR BioPharma Announces Publication of orBec® Clinical Pulmonary Data in Bone Marrow Transplantation
[read more]Tuesday, June 09, 2009
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec® in GI GVHD
[read more]Friday, May 15, 2009
DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments
[read more]Tuesday, March 31, 2009
DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments
[read more]Wednesday, March 25, 2009
DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement with Numoda Corporation
[read more]Monday, March 16, 2009
DOR BioPharma Appoints Gregg Lapointe, CPA, MBA,
to its Board of Directors
[read more]Friday, March 13, 2009
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD, as Chief Medical Officer
[read more]Thursday, February 12, 2009
DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec® in the Treatment of Graft-versus-Host Disease
[read more]Tuesday, January 27, 2009
DOR BioPharma Announces Appointment of Christopher J. Schaber, PhD, to BioNJ Board of Directors
[read more]Monday, January 26, 2009
DOR BioPharma Announces Formation of Acute Radiation Enteritis Medical Advisory Board
[read more]Tuesday, January 20, 2009
DOR BioPharma Announces Engagement of Amper, Politziner & Mattia, LLP as New Auditors
[read more]Monday, January 12, 2009
DOR BioPharma Announces Private Equity Financing of $2.28 Million with Single Institutional Investor
[read more]Tuesday, January 06, 2009
DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis
[read more]Monday, January 05, 2009
DOR BioPharma Receives SPA Clearance from the FDA to Begin Confirmatory Phase 3 Clinical Trial of orBec® in GI GVHD
[read more]
